glp-1 compounding news november 2025 FDA issued 25 warning letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Compounding GLP-1 Drugs - Recent
Description
If you're living with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with a condition like high blood pressure, type 2 diabetes, or high cholesterol, you might be a suitable candidate for the semaglutide weight loss program
This is where needle stick injuries occur
Effects of physical activity and exercise interventions on Alzheimers disease: An umbrella review of existing meta-analyses
GLP-1Ra at doses intended for T2D management Studies have examined the risk of fracture in both obese and non-obese individuals taking GLP-1Ra at doses intended for T2D (such as liraglutide 1.2 mg daily versus 3.0 mg daily for obesity) [75,76,77]
Recent research suggests GLP-1 receptor expression varies across the gastrointestinal tract, with highest concentrations in the colon
